Authors
Latest:
Dr. Abraham on Surgical Improvements in TGCTJohn A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.
Latest:
Dr. D'Orazio on UV Signature Mutations in MelanomaJohn A. D'Orazio, MD, PhD, associate professor, Department of Pediatrics, College of Medicine, University of Kentucky Markey Cancer Center, discusses ongoing research exploring ultraviolet radiation signature mutations in patients with melanoma.
Latest:
Dr. Glaspy on Immunotherapy in Endometrial CancerJohn A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles School of Medicine, discusses immunogenicity in endometrial cancer.
Latest:
Dr. Kosteva on Single-Agent Versus Combination Immunotherapy in NSCLCJohn A. Kosteva, MD, clinical assistant professor of medicine, University of Pennsylvania School of Medicine, Abramson Cancer Center, discusses the adoption of immunotherapy into the treatment paradigm for patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Martignetti on Next-Generation Sequencing in Fallopian Tube CancerJohn A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.
Latest:
Unmet Needs and Future Directions in Care in CLLClosing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.
Latest:
Dr. Araujo on Emerging Data on Radium-223 for Patients With mCRPCJohn C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.
Latest:
Dr. Byrd on Future Directions With Acalabrutinib in CLLJohn C. Byrd, MD, discusses future directions with acalabrutinib in chronic lymphocytic leukemia.
Latest:
Emerging Strategies in the Management of Relapsed/Refractory CLLConsiderations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.
Latest:
Are Surgery and Chemotherapy Sufficient to Treat Locally Advanced Bladder Cancer?The challenge of pelvic failure following contemporary cystectomy has been engaged and the clinical trials to pursue the amelioration of this problem have commenced.
Latest:
John Copland on Patient-Derived Xenografts in Anaplastic Thyroid CancerJohn Copland, PhD, faculty member in the department of cancer biology, Mayo Clinic, explains his research on patient-derived xenograft (PDX) models in anaplastic thyroid cancer.
Latest:
Yale Clinician Meets With Vice President's Staff on Cancer “Moonshot”Patricia M. LoRusso, D.O. was among a group of 15 top cancer researchers and physician-scientists who met in Washington with aides to Vice President Joe Biden on Jan. 8 to discuss his “moonshot†program to advance cancer treatment.
Latest:
Dr. Hainsworth on Selecting Therapy Based on GeneticsJohn D. Hainsworth, MD, co-founder; principal investigator, Sarah Cannon Research Institute, discusses the results of the MyPathway trial, which was an open-label, phase IIa umbrella basket study.
Latest:
News Reports; March 2007News items reported in this issue: 1) 186-Gene Signature in Cancer Stem Cells Predicts Recurrence 2) National Prostate Cancer Coalition Commences Clinical Trial Education Program 3) Concomitant High-Dose Radiation Therapy Plus Cetuximab Improves Locoregional Control and Reduces Mortality, with No Increase in Radiation Therapy%u2013Associated Toxicity in Patients with Advanced Squamous-Cell Carcinoma of the Head and Neck, and more
Latest:
What Oncologists Need to Know About USP and the Recent ClarificationPatients with cancer across the country rely on community oncology practices to provide them with high-quality, coordinated cancer care.
Latest:
Sentinel Lymph Node Test Has No Effect on Overall Survival in Women With Early-Stage Breast CancerIt had been thought that removing the sentinel node and the surrounding lymph nodes would improve survival rates.
Latest:
Dr. de Groot Discusses Altiratinib as Potential Treatment for GlioblastomaJohn F de Groot, MD, nuro-oncologist, MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.
Latest:
Dr. DiPersio on Investigational Targeted Cellular Therapies in AMLJohn F. DiPersio, MD, PhD, discusses the current state of CAR T-cell therapy, dual affinity re-targeting, bi-specific T-cell engagers, and antibody-drug conjugates for acute myeloid leukemia treatment.
Latest:
PARP Inhibitors for Breast and Ovarian CancersPARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.
Latest:
Dr Seymour on the Role of Mutational Profiling in CLLJohn Seymour, MBBS, FRACP, PhD, discusses the role of genetic profiling in the treatment of chronic lymphocytic leukemia.
Latest:
Dr. Seymour on the Design of the ELEVATE-RR Trial in Relapsed/Refractory CLLJohn F. Seymour, MBBS, FRACP, PhD, discusses the design of the phase 3 ELEVATE-RR trial comparing acalabrutinib vs ibrutinib in chronic lymphocytic leukemia.
Latest:
HITECH Lays the Foundation for More Ambitious Outcomes-Based ReimbursementThe US healthcare system has decades of research and anecdotal evidence suggesting the potential transformational power of healthcare information technology (HIT).
Latest:
Dr. Gordan on Molecular Diagnostics in Biliary Tract CancersJohn Gordan, MD, PhD, assistant professor, Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how the adoption of molecular diagnostics has helped further treatment efforts in biliary tract cancers.
Latest:
Dr. Sampson on Nivolumab Monotherapy for Recurrent GlioblastomaJohn H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.
